Morgan Stanley
AAPG

Morgan Stanley’s Ascentage Pharma AAPG Stock Holding History

Morgan Stanley’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Buy
919
+421
+85% +$8.96K ﹤0.01% 6892
2026
Q1 		$11.9K Buy
498
+345
+225% +$8.49K ﹤0.01% 6897
2025
Q4 		$4.01K Sell
153
-50
-25% -$1.64K ﹤0.01% 7105
2025
Q3 		$7.92K Sell
203
-753
-79% -$30.5K ﹤0.01% 6964
2025
Q2 		$37.6K Buy
+956
New +$25.2K ﹤0.01% 6448

Other funds holding AAPG

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Morgan Stanley's AAPG Position: Q2 2026 in Review

Morgan Stanley increased its Ascentage Pharma (AAPG) stake by 85% in Q2 2026, buying an estimated $8.96K and bringing the position to 919 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6892.

Morgan Stanley first reported a position in AAPG in Q2 2025 and has held it in 5 quarters since. The position peaked at $37.6K in Q2 2025. 8 funds tracked by Wall St. Rank hold AAPG as of Q2 2026.

  • Morgan Stanley held 919 shares of Ascentage Pharma worth $16.1K as of Q2 2026.
  • Morgan Stanley bought 421 Ascentage Pharma shares in Q2 2026, an estimated $8.96K.
  • Ascentage Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6892 holding.
  • Morgan Stanley first reported a position in Ascentage Pharma in Q2 2025 and has held it in 5 quarters since.
  • Morgan Stanley's Ascentage Pharma position peaked at $37.6K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held Ascentage Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.